Please use this identifier to cite or link to this item:
|Title:||HTLV-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases||Autores:||Eusebio-Ponce, Emiliana
Candel, F. J.
|Researchers (UNIBE):||Eusebio-Ponce, Emiliana
|Affiliations:||Instituto de Medicina Tropical y Salud Global (IMTSAG)
Instituto de Medicina Tropical y Salud Global (IMTSAG)
|Research area:||Ciencias de la Salud||Keywords:||HTLV-1; ATLL; HAM/TSP; Adult T Cell Leukemia Lymphoma; Emerging risk; Epidemiology; Pathogenesis||Issue Date:||2019||Publisher:||Sociedad Española de Quimioterapia||Source:||Revista Española de Quimioterapia, 32(6), 485-496||Volume:||32||Issue:||6||Start page:||485||End page:||496||Abstract:||
HTLV-1 was the first retrovirus identified as an etiologic agent of human disease [1, 2]. This virus produces several malignancies including Adult T Cell Leukemia-Lymphoma (ATLL) and Tropical Spastic Paraparesis/ HTLV Associated Myelopathy (TSP/HAM) . HTLV-1 spreads through parenteral, sexual, and vertical (mother-to-child) routes . It shares similar routes of transmission with other viruses including HIV and HCV that are often associated in the same patients. There are four known types of HTLV: HTLV-1, HTLV-2, HTLV-3, and HTLV-4. HTLV-1 is the most pathogenic for humans while HTLV-2 usually produces mild neurological disease. Both are prevalent worldwide. HTLV-3 and HTLV-4 have been identified only in Central Africa and usually affect non-human hominids . The striking geographical distribution of the virus through Japan, West Africa and Latin America-Caribbean regions is still an unresolved puzzle. This, together with the pathogenesis, epidemiology, diagnosis, associated diseases, preventive strategies and treatments will be critically analyzed in this review, highlighting the emerging risk for Europe, exemplified with the case of Spain, and the prevention strategies to avoid it.
|Appears in Collections:||Publicaciones del IMTSAG-UNIBE|
Show full item record Recommend this item
Files in This Item:
|revespquimioter-32-485.pdf||Open access [full text]||770.33 kB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License